Moreover, immune checkpoint inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), which significantly improve survival outcomes for patients with advanced CM, have shown no clinical benefit in patients with metastatic UM [25,26,27,28]. This evidence concerns the gene CTLA4 and cutaneous mastocytosis.